profit from every CHF 100 of sales.
CHF 0CHF 100
Sonova
CHF 286.20+2.95% today
+39.0% in 1 year
1-year low CHF 168.051-year high CHF 292.20
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay CHF 39.57 for every CHF 1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Sonova sold, what it kept, and what it did with the cash.
Sales went from CHF 3.74 billion in 2023 to CHF 3.61 billion in 2026, with CHF 431 million of profit last year.
SalesProfit
Sonova handed back 52% of the cash it generated last year.
CHF 262M
Free cash flow 2026CHF 632M
Bought back its own sharesCHF 63M
Paid as dividendsCHF 262M
Cash vs. debtCHF 722M vs. CHF 1.7B
Sonova vs. similar companies
Sonova grows the slowest of these 5 and is priced in the middle for its profits.
| Company | Profit from CHF 100 of sales | Sales growth a year | Price per CHF 1 of profit |
|---|---|---|---|
| Sonova | 39.6× · Expensive | ||
 Abbott Laboratories | 28.8× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 36.3× · Expensive | ||
 Edwards Lifesciences | 57.4× · Expensive |
AI analysis
An AI analyst reads Sonova's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CHF | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 3,738 | 3,627 | 3,613 | 3,606 | |
| 2,637 | 2,610 | 2,684 | 2,658 | |
| 747 | 670 | 720 | 676 | |
| 979 | 922 | 944 | 931 | |
| 648 | 601 | 541 | 431 | |
| 10.72 | 10.05 | 9.04 | 7.22 | |
| 70.5% | 72.0% | 74.3% | 73.7% | |
| 20.0% | 18.5% | 19.9% | 18.7% | |
| 17.3% | 16.6% | 15.0% | 11.9% |
Balance sheet
| In millions of CHF | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 5,553 | 5,792 | 5,924 | 5,629 |
| Cash | 414 | 514 | 687 | 722 |
| Total debt | 1,815 | 1,795 | 1,761 | 1,712 |
| Total liabilities | 3,321 | 3,301 | 3,240 | 2,993 |
| 2,212 | 2,470 | 2,665 | 2,614 | |
| 60 | 60 | 60 | 60 | |
| 15.6% | 13.5% | 13.7% | 13.2% | |
| 29.3% | 24.3% | 20.3% | 16.5% |
Cash flow
| In millions of CHF | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 784 | 753 | 790 | 735 | |
| 154 | 129 | 132 | 103 | |
| 630 | 625 | 659 | 632 | |
| Dividends paid | 268 | 274 | 256 | 262 |
| 503 | 51 | 67 | 63 | |
| 21 | 23 | 20 | 19 |
Valuation
- 39.6×
- –
- –
- 4.5×
- 4.7×
- 27.0×
- 19.4×
- 3.7%
- 2.5%
- 1.5%
Profitability
- 73.7%
- 18.7%
- 11.9%
- –
- 13.2%
- 14.0%
- –
- –
- –
- –
Growth
- −1.2%
- −12.3%
- –
- –
- −0.4%
Financial health
- 1.1×
- 0.65
- –
- 23.4×
- 1.75
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 18%of 963
Top 28%of 894
Bottom 32%of 632
Bottom 15%of 908
Top 31%of 991
1.5%of the share price, paid each year
On $1,000 invested$15a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
60.9% of its profit
Room to growStretchedMore than it earns: 41.5%
News
Jim Cramer: Amazon Has What “May Soon Be a $50 Billion Semiconductor Business”Yahoo Finance · Nov 14, 2026Tech stocks may soon enjoy a ‘violent bounce’ — but one strategist warns investors not to take the baitMarketWatch · Nov 12, 2026Looking to buy the dip in chip stocks? Here’s how to avoid buying too soon.MarketWatch · Nov 10, 2026Nvidia could soon face tougher export rules, making it harder to sell chips to China after scandalMarketWatch · Nov 10, 2026Interest rates could go ‘significantly higher’ if oil prices keep climbing — even if the Iran war ends soonMarketWatch · Nov 5, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
59No pass
Benjamin Graham
36No pass
Philip Fisher
46No pass
Peter Lynch
22No pass
Joel Greenblatt
16No pass
Charlie Munger
54No pass
Terry Smith
52No pass
Questions about Sonova
Is Sonova a good stock to buy?
A solid business, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Sonova AI analysis
What does Sonova do?
Sonova Holding AG manufactures and sells hearing care solutions for children and adults in Switzerland, the United States, rest of the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It is in Medical Devices, based in Stäfa, Switzerland, with 18,570 employees.
Does Sonova pay a dividend?
Yes. At today's price the dividend is 1.5% a year, about 61% of its yearly profit. In 2026 it paid out CHF 262 million in dividends.
Is Sonova stock halal?
Yes. Sonova passes our halal screen: its business is permitted and its debt is 10% of its market value, under the 30% limit. How we check
How has Sonova stock done over the past year?
Up 39.0% over the past twelve months, to CHF 286.20. It traded between CHF 168.05 and CHF 292.20 and is 2.1% below its high.
Who are Sonova's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Sonova's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.